Kepivance®
Company
Amgen, Inc.
Use
Treatment of severe mouth sores that afflict hematologic cancer patients who receive myelotoxic therapy
Features
Improves the most debilitating side effect cited for blood cancer therapy
NIH Contribution
Characterized the effects of the chemical palifermin which is a human keratinocyte growth factor (KGF)
Approval Type
FDA
HHS Institute/Agency
NCI
Inventor(s)
J. Rubin
Year
2004
Tech Cat
Biologic
Request More Info
